Patents Assigned to Bayer Aktiengesellschaft
-
Publication number: 20230346927Abstract: The present invention covers combinations of at least two components, component A and component B, comprising component A being an inhibitor of ATR kinase, particularly an inhibitor of ATR kinase selected from VX-803, VX-970, AZD-6738, a compound of general formula (I) described herein, a compound of general formula (Ib) described herein and Compound A described infra, and component B being a PD-1/PD-L1 inhibitor described herein. Another aspect of the present invention covers the use of such combinations as described herein for the preparation of a medicament for the treatment or prophylaxis of a disease, particurlarly for the treatment of a hyper-proliferative disease.Type: ApplicationFiled: May 25, 2023Publication date: November 2, 2023Applicants: Bayer Aktiengesellschaft, Bayer Pharma AktiengesellschaftInventor: Antje Margret Wengner
-
Publication number: 20230348392Abstract: The present disclosure relates to pyridine (thio)amide compounds, processes and intermediates for their preparation as well as the uses thereof for controlling phytopathogenic microorganisms, such as phytopathogenic fungi.Type: ApplicationFiled: May 4, 2021Publication date: November 2, 2023Applicant: Bayer AktiengesellschaftInventors: Julie GEIST, Anthony MILLET, Anne-Sophie REBSTOCK, Cyril MONTAGNE, Lionel NICOLAS, Valerie TOQUIN, Mathieu GOURGUES, Dominique LOQUE, Vincent THOMAS, Mazen ES-SAYED (DECEASED), Alexander SUDAU
-
Publication number: 20230339899Abstract: The present invention relates to a process for preparing a tetrazole-substituted anthranilic acid diamide derivative according to formula (I) in crystalline form via solvate crystals in high purity and high yield. The present invention also further relates to the provision of novel solvate crystals which are distinguished by improved filtration properties compared to a tetrazole-substituted anthranilic acid diamide derivative according to the abovementioned formula (I) in crystalline form.Type: ApplicationFiled: September 2, 2021Publication date: October 26, 2023Applicant: Bayer AktiengesellschaftInventors: Daniel GALLENKAMP, Edith BECKMANN, Ute ELIAS, Dirk HAVEKOST, Michal SOWA, Britta OLENIK
-
Patent number: 11795164Abstract: The present invention covers 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamide compounds of general formula (1): in which X, R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer or conditions with dysregulated immune responses or other disorders associated with aberrant AHR signaling, as a sole agent or in combination with other active ingredients.Type: GrantFiled: August 12, 2022Date of Patent: October 24, 2023Assignees: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, Deutsches KrebsforschungszentrumInventors: Ilona Gutcher, Norbert Schmees, Lars Röse, Benjamin Bader, Christina Kober, Rafael Carretero, Detlef Stöckigt, Horst Irlbacher, Michael Platten
-
Publication number: 20230329221Abstract: The present disclosure relates to the control of plants which appear as undesirable matter in a field for crop plants by means of electrical energy.Type: ApplicationFiled: October 28, 2019Publication date: October 19, 2023Applicant: Bayer AktiengesellschaftInventors: Christoph BREITENSTROETER, Sergio JIMENEZ TARODO, James HADLOW
-
Patent number: 11787797Abstract: The present invention provides triazolone compounds of general formula (I): in which R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients.Type: GrantFiled: January 28, 2021Date of Patent: October 17, 2023Assignees: BAYER AKTIENGESELLSCHAFT, BAYER PHARMA AKTIENGESELLSCHAFT, THE BROAD INSTITUTE, INC., PRESIDENT AND FELLOWS OF HARVARD COLLEGE, THE GENERAL HOSPITAL CORPORATIONInventors: Stefan Nikolaus Gradl, Duy Nguyen, Knut Eis, Judith Günther, Timo Stellfeld, Andreas Janzer, Sven Christian, Thomas Mueller, Sherif El Sheikh, Han Jie Zhou, Changjia Zhao, David B. Sykes, Steven James Ferrara, Kery Liu, Simon Anthony Herbert, Claudia Merz, Michael Niehues, Carl Friedrich Nising, Martina Schäfer, Katja Zimmermann, Jörg Knäblein, Kai Thede, Thomas Faupel
-
Patent number: 11786615Abstract: The invention provides a unit operation formed by a device and its use for continuous virus inactivation of a continuous flow of a process fluid. The unit operation formed by a device comprises a single inlet at one end and an outlet at the opposite end and at least one HFI, characterized in that the HFI further comprises at least one installation.Type: GrantFiled: September 18, 2018Date of Patent: October 17, 2023Assignee: Bayer AktiengesellschaftInventors: Martin Lobedann, Laura David, Sven-Oliver Borchert, Lisa Marie Waldschmidt
-
Patent number: 11771074Abstract: The present disclosure relates to the sensor based observation of arthropods in a region where plants grow. The subject matter of the present disclosure is a device, system, method and computer program product for the sensor based observation of arthropods, by means of a camera.Type: GrantFiled: September 16, 2019Date of Patent: October 3, 2023Assignee: Bayer AktiengesellschaftInventors: Robert Wollenhaupt, Dennis Göke, Stefan Gröger, Ernst-Georg Schmid
-
Patent number: 11773070Abstract: The present invention provides dihydrooxydiazinone compounds of general formula (I) in which R1, R2, R3, and R4, are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative diseases, as a sole agent or in combination with other active ingredients.Type: GrantFiled: July 14, 2022Date of Patent: October 3, 2023Assignees: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.Inventors: Manuel Ellermann, Stefan Nikolaus Gradl, Charlotte Christine Kopitz, Martin Lange, Adrian Tersteegen, Philip Lienau, Christa Hegele-Hartung, Detlev Sülzle, Timothy A. Lewis, Heidi Greulich, Xiaoyun Wu, Matthew Meyerson, Alex Burgin
-
Publication number: 20230303647Abstract: The present invention relates to cyclic chemerin-9 derivatives of general formula (I) as described and defined herein, methods of preparing said peptides, and the use of said compounds for the treatment or prophylaxis of diseases, in particular cancer, diabetes, obesity and inflammatory disorders.Type: ApplicationFiled: August 10, 2021Publication date: September 28, 2023Applicant: Bayer AktiengesellschaftInventors: Jan Robert KRÄHLING, Bernd RIEDL, Annette BECK-SICKINGER, Tobias FISCHER, Anne CZERNIAK, Sylvia ELS-HEINDL
-
Publication number: 20230301969Abstract: The present invention provides N-(2-chloro-6-fluorophenyl)-4-[4-ethyl-3-(hydroxymethyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]-5-fluoro-2-{[(2S)-1,1,1-trifluoropropan-2-yl]oxy}benzamide for use in a method of cancer treatment using a dose schedule of daily dosing on equal to 4 days up to 5 days followed by a short off period of equal to 2 days up to 3 days, as well as a method of treatment of cancer diseases with a composition comprising said DHODH inhibitor using the new dosing schedule.Type: ApplicationFiled: August 24, 2021Publication date: September 28, 2023Applicant: Bayer AktiengesellschaftInventor: Andreas JANZER
-
Publication number: 20230295138Abstract: The present disclosure relates to heterocyclyl pyridine compounds, processes and intermediates for their preparation as well as the uses thereof for controlling phytopathogenic microorganisms, such as phytopathogenic fungi.Type: ApplicationFiled: June 1, 2021Publication date: September 21, 2023Applicant: Bayer AktiengesellschaftInventors: Julie GEIST, Anthony MILLET, Cyril MONTAGNE, Lionel NICOLAS, Tomoki TSUCHIYA, Dominique LOQUE, Vincent THOMAS
-
Patent number: 11763924Abstract: The invention relates to the technical field of supporting patients in the repeated taking of drugs within the context of a therapeutic treatment. The invention relates to a method, to a system, and to a computer program product that monitor the taking of drugs by a patient and inform the patient or a doctor or another person if a drug portion should not be taken in order to thus optimize the effectiveness of the treatment or reduce risks.Type: GrantFiled: March 16, 2018Date of Patent: September 19, 2023Assignee: Bayer AktiengesellschaftInventors: Hubert Trübel, Philip Patrick Böhme, Martin Van Eickels, Wilfried Dinh, Frank Kramer, Carlos Castellon
-
Publication number: 20230278994Abstract: The present disclosure relates to heterocyclyl pyrimidine and heterocyclyl triazine compounds, processes and intermediates for their preparation as well as the uses thereof for controlling phytopathogenic microorganisms, such as phytopathogenic fungi.Type: ApplicationFiled: June 1, 2021Publication date: September 7, 2023Applicant: Bayer AktiengesellschaftInventors: Julie GEIST, Anthony MILLET, Cyril MONTAGNE, Lionel NICOLAS, Tomoki TSUCHIYA, Vincent THOMAS
-
Publication number: 20230270729Abstract: The use of P2X4 antagonists for the treatment of dry eye syndrome, more in particular substituted N-phenylacetamide compounds of general formula (I), pharmaceutical compositions and combinations comprising said compounds for use in the treatment or prophylaxis of dry eye syndrome and in particular dry eye, ocular neuropathic pain, ocular trauma and post-operative ocular pain.Type: ApplicationFiled: June 28, 2021Publication date: August 31, 2023Applicants: Bayer Aktiengesellschaft, The Johns Hopkins UniversityInventors: Stefan BÄURLE, William SCHUBERT, Jens NAGEL, Carsten TERJUNG, David FINIS, Samuel YIU, Hui LIN, Minjie CHEN, Stefanie SEO
-
Publication number: 20230257351Abstract: Substituted N-phenylacetamide compounds of general formula (I), methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases.Type: ApplicationFiled: June 28, 2021Publication date: August 17, 2023Applicant: Bayer AktiengesellschaftInventors: Stefan BÄURLE, Sven RING, Jens NAGEL, Alexis LAUX-BIEHLMANN, Reinhard NUBBEMEYER, Elisabeth POOK, Sven WITTROCK, Daryl Simon WALTER, Robert John SCOTT
-
Patent number: 11727571Abstract: The present disclosure deals with the quickening of MRI examinations. Subjects of the present disclosure are a method, a system, a computer program product, a use, a contrast agent for use and a kit.Type: GrantFiled: September 14, 2020Date of Patent: August 15, 2023Assignee: BAYER AKTIENGESELLSCHAFTInventors: Martin Rohrer, Arthur Uber, III
-
Publication number: 20230240299Abstract: The present invention aims to provide a composition for controlling Cercospora leaf spot of beet causing serious damage in beet cultivation, and a method for controlling Cercospora leaf spot of beet using the composition for controlling said disease. The present invention relates to a composition for controlling Cercospora leaf spot of beet comprising isotianil, and a method for controlling Cercospora leaf spot of beet comprising applying a composition for controlling Cercospora leaf spot of beet comprising isotianil at least once. The composition for controlling Cercospora leaf spot of beet of the present invention may further comprise a controlling agent for Cercospora leaf spot of beet other than isotianil.Type: ApplicationFiled: June 18, 2021Publication date: August 3, 2023Applicant: Bayer AktiengesellschaftInventors: Takashi OKADA, Kotomi HAYASHI, Shiho TAKAMURA, Masahito NIKI, Takuma MORI, Tomomi AOKI
-
Patent number: 11712440Abstract: The present invention covers an ATR kinase inhibitor, particularly 2-[(3R)-3-methylmorpholin-4-yl]-4-(1-methyl-1H-pyrazol-5-yl)-8-(H-pyrazol-5-yl)-1,7-naphthyridine (“Compound A”), for use in the treatment of a hyper-proliferative disease in a subject, wherein the hyper-proliferative disease or the subject is or has been characterized by one or more biomarker(s), wherein the biomarker(s) comprise(s) a) one or more functional mutations in one or more gene(s)/protein(s) selected from RBBP8, APOBEC3A, APOBEC3B, CLSPN, ERCC, HUS1, MAD2L2, PGBD5, POLD1, RAD1, TIMELESS and/or TIPIN; and/or b) the expression of a fusion gene encoding a fusion protein selected from EWSR-ERG, EWSR1-FLI1, SS18-SSX and/or SS18-SSX2 gene/protein.Type: GrantFiled: December 4, 2018Date of Patent: August 1, 2023Assignee: Bayer AktiengesellschaftInventors: Antje Margret Wengner, Gerhard Siemeister, Li Liu
-
Patent number: 11713304Abstract: The present invention provides triazolone compounds of general formula (I): in which R1, R2, R3, R4, and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and prophylaxis of diseases, in particular hyperproliferative disorders, as a sole agent or in combination with other active ingredients.Type: GrantFiled: August 20, 2021Date of Patent: August 1, 2023Assignees: BAYER AKTIENGESELLSCHAFT, BAYER PHARMA AKTIENGESELLSCHAFT, THE BROAD INSTITUTE, INC., PRESIDENT AND FELLOWS OF HARVARD COLLEGE, THE GENERAL HOSPITAL CORPORATIONInventors: Stefan Nikolaus Gradl, Duy Nguyen, Knut Eis, Judith Günther, Timo Stellfeld, Andreas Janzer, Sven Christian, Thomas Müller, Sherif El Sheikh, David B. Sykes, Steven James Ferrara, Michael Kröber, Claudia Merz, Michael Niehues, Martina Schäfer, Katja Zimmermann, Carl Friedrich Nising